CDXI has former CFO of Novartis, wow!!
$CDXI Offers Alternative to Tylenol, Secures Major Partnerships
(NEW YORK)--Cardax, Inc. (OTC:CDXI), a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress, closes major agreements to develop new anti-inflammatory products.
Alternative to Acetaminophen (Tylenol)
As many have become aware over the past few years, the use of popular over-the-counter pain relievers containing acetaminophen, such as with Tylenol and other name brand pain relievers, has shown to cause liver damage from overuse, especially people prone to liver issues.
An example, if you did not know, it is highly recommended you don't take acetaminophen products to treat a hangover as the effects of the acetaminophen, and the bodies processing of the alcohol, has shown to cause extreme stress on the liver, and under prolonged use can cause permanent damage.
In addition, there are also issues with people with standing liver disease (unrelated to alcohol) who also can not benefit from the effects of acetaminophen as an over-the-counter pain reliever. This sets up a multi-billion dollar market for alternatives to this popular over-the-counter medicine, and CDXI has that with astaxanthin.
Experienced Board of Directors
If you want to get a good idea on why CDXI stands out from most other penny stocks, then take a look at just a sample of who sits on their Board of Directors.
Mr. George Bickerstaff held various positions with Novartis International AG, a global pharmaceuticals and consumer health company, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. Ms. Tamar Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb from 2001 to 2007.
Mr. Bickerstaff and Ms. Howson, are both currently members of the Board of Directors with CDXI.
Major Partnership Agreements
CDXI recently closed partnership deals with BASF and Capsugel to develop and bring new anti-inflammatory products to market, and commercialization under revenue sharing agreements.
BASF, the world's largest chemical company, has licensed exclusive rights from CDXI for the commercialization of nature-identical, synthetic astaxanthin, ASTX-1, as a nutraceutical. With lower regulatory restrictions on nutraceuticals, the product approval and introduction should move much faster than a pharmaceutical drug, allowing BASF and CDXI to have a product available for sale in 2015.
Add together CDXI experienced Board with years of history in major pharmaceutical companies, their partnership agreements with major drug developers, and a product that provides an alternative to popular over-the-counter drugs, such as Tylenol, and CDXI may be one of those few "real deal" companies not normally found on the OTC exchange.